Staging with PET and the "Will Rogers" effect: Redefining prognosis and survival in patients with cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 1, 2008, Pages 1-4

  Basu, Sandip ^a,b   Alavi, Abass ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE SEVERITY; EDITORIAL; HUMAN; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 36849038913     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0506-2     Document Type: Editorial

References (36)

1. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-8.
2. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer-a meta-analysis. Ann Intern Med 2003;139:879-92.
3. Mavi A, Lakhani P, Zhuang H, Gupta NC, Alavi A. Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am 2005;43:1-21.
4. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF. Results of the American College of Surgeons Oncology Group Z0050 Trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;126:1943-51.
5. Verhagen AFT, Bootsma GP, Tjan-Heijnen VCG, van der Wilt GJ, Cox AL, Brouwer MHJ. FDG-PET in staging lung cancer-how does it change the algorithm? Lung Cancer 2004;44:175-81.
6. Schiepers C, Filmont JE, Czernin J.PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S82-8.
7. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
8. Skehan SJ, Brown AL, Thompson M, Young JE, Coates G, Nahmias C. Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics 2000;20:713-23.
9. Basu S, Alavi A. Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites? Eur J Nucl Med Mol Imaging 2007;34:604-5.
10. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol 2005;6:864-70.
11. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6:659-68.
12. 18F]fluorodeoxyglucose positron emission tomography in this setting. J Clin Oncol 2007;25:1297.
13. Becker S, Becker-Pergola G, Wallwiener D, Solomayer EF, Fehm T. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Res Treat 2006;97:91-6.
14. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7.
15. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S89-96.
16. Kumar R, Maillard I, Schuster SJ, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am 2004;42:1083-100.
17. 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33.
18. 18F)- fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001;15:272-8.
19. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-9.
20. Weihrauch M, Re D, Scheidhauer K, Ansén S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using F-18-FDG for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930-4.
21. 18F)2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002;16:260-7.
22. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001;12:29-37.
23. Couper GW, McAteer D, Wallis F, Norton M, Welch A, Nicolson M, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998;85:1403-6.
24. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65.
25. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361-8.
26. Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron tomography. Ann Surg 2001;233:300-9.
27. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, et al. Usefulness of positron emission tomography for assessing the response to neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002;184:279-83.
28. Nakamura R, Obara T, Katsuragawa S. Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after RT. Radiat Med. 2002;20:181-6.
29. 18FDG PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428-32.
30. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004;45(1):56-68, Jan.
31. Zhuang H, Yu JQ, Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 2005;43:121-34.
32. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 2004;34:313-29.
33. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation.Semin Nucl Med. 2002;32:47-59.
34. Alavi A, Zhuang H. Finding infection-help from PET. Lancet. 2001;358:1386.
35. Bombardieri E. The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment. Eur J Nucl Med Mol Imaging 2006;33:753-8.
36. 18F-FDG accumulation in the distal oesophagus. Eur J Nucl Med Mol Imaging 2005;32:990-2.